New angiogenesis regulators
The invention discloses for the first time the TMEM230 regulator in the treatment of diseases where angiogenesis modulation is needed for therapeutic purposes. The modulation of TMEM230 has a therapeutic effect on different disease as it induces a response in an animal or human tissue, alleviating the symptoms of disease.
TMEM230 gene and protein sequences are conserved in vertebrate species. The inventors both on the Zebrafish animal model and on human endothelial cells (HUVEC) in three-dimensional (3D) culture conditions, have shown that the over-regulation of TMEM230 causes the cells to acquire migratory capacities with the related formation of new blood vessels. In contrast, its down-regulation causes the loss of the ability of HUVEC cells to generate new blood vessels. Therefore TMEM230 can be a pharmacological target to promote, inhibit and regulate in vitro angiogenesis, finding application for the treatment of all those pathologies which require angiogenesis regulation both in positive and in negative. For example, neo-angiogenesis is essential for the metastatic properties of tumor cells: TMEM230 can be a therapeutic target for the treatment of cancer and metastasis.
- Diseases which require an increase of angiogenesis;
- Diseases which require a reduction of angiogenesis, such as invasive and metastatic tumors.
The therapeutic target here identified, for the treatment of pathologies that require regulation of angiogenesis, is relevant:
- Positive (induction of angiogenesis);
- Negative (inhibition of angiogenesis).